The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2026 | Comparing the patient experience with CAR-T versus transplant in LBCL
In this video, Lorna Warwick, BA, Lymphoma Coalition, Toronto, Canada, briefly outlines findings from the Lymphoma Coalition’s 2024 global patient survey comparing the decision-making experience in patients with large B-cell lymphoma undergoing stem cell transplantation versus CAR T-cell therapy. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
With our poster at EBMT, we’re looking at an analysis of patients from our global patient survey that we do every two years. This is the 2024 version of the survey, which is the data used. And we looked at those who had been treated with CAR-T versus those treated with a stem cell transplant and looked at shared decision-making and different elements that contribute to shared decision-making between the two cohorts...
With our poster at EBMT, we’re looking at an analysis of patients from our global patient survey that we do every two years. This is the 2024 version of the survey, which is the data used. And we looked at those who had been treated with CAR-T versus those treated with a stem cell transplant and looked at shared decision-making and different elements that contribute to shared decision-making between the two cohorts. And there was definitely a gap for those who go through stem cell transplant. CAR-T patients were much more likely to say that they were involved in the decisions about their care, they were more likely to say that they had better relationships with their doctor, that the doctor responds to their questions and answers in a way that they understood and overarchingly felt like they were more involved and had a better relationship with their doctor to discuss these kinds of issues. Stem cell transplant, definitely not. So it does show a gap in care that could be addressed in clinic to make the overarching experience easier for patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
